Literature DB >> 1311717

Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms.

M R Bristow1, W Minobe, R Rasmussen, P Larrabee, L Skerl, J W Klein, F L Anderson, J Murray, L Mestroni, S V Karwande.   

Abstract

In order to investigate the general cause of beta-adrenergic receptor neuroeffector abnormalities in the failing human heart, we measured ventricular myocardial adrenergic receptors, adrenergic neurotransmitters, and beta-adrenergic receptor-effector responses in nonfailing and failing hearts taken from nonfailing organ donors, subjects with endstage biventricular failure due to idiopathic dilated cardiomyopathy (IDC), and subjects with primary pulmonary hypertension (PPH) who exhibited isolated right ventricular failure. Relative to nonfailing PPH left ventricles, failing PPH right ventricles exhibited (a) markedly decreased beta 1-adrenergic receptor density, (b) marked depletion of tissue norepinephrine and neuropeptide Y, (c) decreased adenylate cyclase stimulation in response to the beta agonists isoproterenol and zinterol, and (d) decreased adenylate cyclase stimulation in response to Gpp(NH)p and forskolin. These abnormalities were directionally similar to, but generally more pronounced than, corresponding findings in failing IDC right ventricles, whereas values for these parameters in nonfailing left ventricles of PPH subjects were similar to values in the nonfailing left ventricles of organ donors. Additionally, relative to paired nonfailing PPH left ventricles and nonfailing right ventricles from organ donors, failing right ventricles from PPH subjects exhibited decreased adenylate cyclase stimulation by MnCl2. These data indicate that: (a) Adrenergic neuroeffector abnormalities present in the failing human heart are due to local mechanisms; systemic processes do not produce beta-adrenergic neuroeffector abnormalities. (b) Pressure-overloaded failing right ventricles of PPH subjects exhibit decreased activity of the catalytic subunit of adenylate cyclase, an abnormality not previously described in the failing human heart.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1311717      PMCID: PMC442925          DOI: 10.1172/JCI115659

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  49 in total

1.  Neurotransmitter depletion compromises the ability of indirect-acting amines to provide inotropic support in the failing human heart.

Authors:  J D Port; E M Gilbert; P Larrabee; P Mealey; K Volkman; R Ginsburg; R E Hershberger; J Murray; M R Bristow
Journal:  Circulation       Date:  1990-03       Impact factor: 29.690

2.  Plasma norepinephrine in congestive heart failure.

Authors:  J A Thomas; B H Marks
Journal:  Am J Cardiol       Date:  1978-02       Impact factor: 2.778

3.  Localization of a "postreceptor" defect in human dilated cardiomyopathy.

Authors:  M Böhm; P Gierschik; K H Jakobs; P Schnabel; B Kemkes; E Erdmann
Journal:  Am J Cardiol       Date:  1989-10-01       Impact factor: 2.778

4.  A simplification of the protein assay method of Lowry et al. which is more generally applicable.

Authors:  G L Peterson
Journal:  Anal Biochem       Date:  1977-12       Impact factor: 3.365

5.  Beta-adrenergic receptor number and adenylate cyclase function in denervated transplanted and cardiomyopathic human hearts.

Authors:  A R Denniss; J D Marsh; R J Quigg; J B Gordon; W S Colucci
Journal:  Circulation       Date:  1989-05       Impact factor: 29.690

6.  Decreased adrenergic neuronal uptake activity in experimental right heart failure. A chamber-specific contributor to beta-adrenoceptor downregulation.

Authors:  C S Liang; T H Fan; J T Sullebarger; S Sakamoto
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

7.  Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy.

Authors:  M R Bristow; F L Anderson; J D Port; L Skerl; R E Hershberger; P Larrabee; J B O'Connell; D G Renlund; K Volkman; J Murray
Journal:  Circulation       Date:  1991-09       Impact factor: 29.690

8.  Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity.

Authors:  G J Hasking; M D Esler; G L Jennings; D Burton; J A Johns; P I Korner
Journal:  Circulation       Date:  1986-04       Impact factor: 29.690

9.  Decreased Gs alpha mRNA levels accompany the fall in Gs and adenylyl cyclase activities in compensated left ventricular hypertrophy. In heart failure, only the impairment in adenylyl cyclase activation progresses.

Authors:  L A Chen; D E Vatner; S F Vatner; L Hittinger; C J Homcy
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

10.  Regional distribution of beta-adrenoceptors in the human heart: coexistence of functional beta 1- and beta 2-adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy.

Authors:  O E Brodde; S Schüler; R Kretsch; M Brinkmann; H G Borst; R Hetzer; J C Reidemeister; H Warnecke; H R Zerkowski
Journal:  J Cardiovasc Pharmacol       Date:  1986 Nov-Dec       Impact factor: 3.105

View more
  76 in total

Review 1.  MIBG imaging.

Authors:  Amar D Patel; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

2.  Impaired cardiac adrenergic innervation assessed by MIBG imaging as a predictor of treatment response in childhood dilated cardiomyopathy.

Authors:  P Acar; P Merlet; L Iserin; D Bonnet; D Sidi; A Syrota; J Kachaner
Journal:  Heart       Date:  2001-06       Impact factor: 5.994

3.  Chamber-specific alterations of noradrenaline uptake (uptake(1)) in right ventricles of monocrotaline-treated rats.

Authors:  K Leineweber; T Seyfarth; O E Brodde
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

4.  Imaging of cardiac adrenergic innervation.

Authors:  P G Camici
Journal:  Heart       Date:  2002-09       Impact factor: 5.994

5.  Myofibrillar calcium sensitivity of isometric tension is increased in human dilated cardiomyopathies: role of altered beta-adrenergically mediated protein phosphorylation.

Authors:  M R Wolff; S H Buck; S W Stoker; M L Greaser; R M Mentzer
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

Review 6.  The adrenergic system in pulmonary arterial hypertension: bench to bedside (2013 Grover Conference series).

Authors:  Michael R Bristow; Robert A Quaife
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

Review 7.  Alterations in adrenergic receptor signaling in heart failure.

Authors:  S Lamba; W T Abraham
Journal:  Heart Fail Rev       Date:  2000-03       Impact factor: 4.214

8.  Carvedilol tratment of chronic heart failure: a new era.

Authors:  M Bristow
Journal:  Heart       Date:  1998-06       Impact factor: 5.994

Review 9.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

10.  Heart failure causes cholinergic transdifferentiation of cardiac sympathetic nerves via gp130-signaling cytokines in rodents.

Authors:  Hideaki Kanazawa; Masaki Ieda; Kensuke Kimura; Takahide Arai; Haruko Kawaguchi-Manabe; Tomohiro Matsuhashi; Jin Endo; Motoaki Sano; Takashi Kawakami; Tokuhiro Kimura; Toshiaki Monkawa; Matsuhiko Hayashi; Akio Iwanami; Hideyuki Okano; Yasunori Okada; Hatsue Ishibashi-Ueda; Satoshi Ogawa; Keiichi Fukuda
Journal:  J Clin Invest       Date:  2010-01-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.